Patient-Derived Cells (PDC)

Patient-derived cells are primary cells isolated directly from patient tumor tissue and used without the extended culture that converts a primary population into an established line. The distinction matters because the conversion is not neutral. An established line is the product of decades of selection for growth in plastic, and the population that emerges is the subset best suited to those conditions rather than the population present in the tumor.

Altogen Labs isolates and characterizes patient-derived cells for assay work where primary material is required and an established line would not represent the relevant biology. To discuss a program, request a quote.

Where primary cells are the right choice

Primary cells are appropriate where the question concerns a specific donor, where the target is expressed in primary tumor but lost or altered in established lines, where donor-to-donor variability is itself the object of study, or where a mechanism depends on cellular heterogeneity that a clonally selected line no longer contains.

They are the wrong choice where the requirement is a reproducible, indefinitely available substrate for a screening cascade. Primary cells have finite proliferative capacity, yield varies between donors, and the material is exhausted. Where those constraints bind, an established line in in vitro oncology work is the correct platform and the primary material is better reserved for the questions that require it.

Isolation and characterization

Tissue is dissociated under conditions selected for the tumor type, since dissociation method determines which populations survive and which surface epitopes remain detectable. An aggressive protocol can deplete the population of interest, and this is a common and silent cause of a failed primary assay.

Characterization covers viability and yield, identity confirmation that the isolated population is tumor rather than infiltrating or adjacent normal cells, and phenotyping by flow cytometry where the relevant population must be defined by surface markers. Target expression is confirmed before a target-directed assay is run rather than assumed from the donor pathology report.

Applications

Applications include cytotoxicity and sensitivity testing on donor-specific material, target expression profiling in primary tumor cells, mechanistic work in a genetic background matching a specific donor, and provision of primary cells as effector or target material for immuno-oncology assays.

Applied examples

Donor-specific sensitivity. Cells isolated from an individual donor are tested against candidate agents, providing a response profile for that donor’s tumor rather than for a line of the same histology.

Target expression confirmation. Primary cells are phenotyped for target expression before a target-directed agent is evaluated, establishing whether the donor’s tumor expresses the target at all.

Primary versus line comparison. The same agent is tested against primary cells and an established line of matching histology, quantifying the divergence between them for that compound class.

Constraints and documentation

Yield is variable and depends on tissue quantity, viability at receipt, and tumor type, so assay plans account for the possibility that a given sample yields less material than required. Primary cells have limited proliferative capacity, which constrains the number of conditions testable from one donor and makes assay prioritization a design decision rather than an afterthought.

Patient-derived material requires institutional review board approval and written informed consent, and provenance documentation is maintained from receipt. Isolation method, yield, viability, and characterization performed are recorded per donor. Surplus material is cryopreserved where viability permits, so a later question can be addressed without new tissue.

Send indication, required cell type, and assay objectives, or request a quote.